Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Vanda To Pay Eli Lilly Up To $100 Million In Drug Development Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2012 | 01:50pm CEST

Vanda Pharmaceuticals Inc. (>> Vanda Pharmaceuticals Inc.) agreed to pay Eli Lilly Co. (LLY) up to $100 million for the exclusive right to develop a drug that has shown some promise as a treatment for alcohol addiction.

Under its deal with Lilly, the biopharmaceutical company will pay a $1 million initial license fee and take responsibility for all development costs of the VLY-686 drug.

Lilly is also eligible to receive additional payments based upon certain milestones and royalties on sales. These milestones include $4 million for milestones achieved prior to a new drug application and up to $95 million for future regulatory approval and sales milestones.

Vanda, which focuses on treatments for central nervous system disorders, noted that prior research of VLY-686 has focused on its potential as a novel therapeutic for individuals struggling with dependence on alcohol.

"The licensing of VLY-686 is an important milestone for Vanda, as we continue to realize our vision of developing treatments to address unmet medical needs," said Chief Executive Mihael H. Polymeropoulos.

Vanda in February reported it swung to a loss in the fourth quarter as increased expenses outweighed higher revenue for the period.

Shares closed Friday at $4.49 and were inactive in premarket trade. The stock has slumped 42% over the past year.

-By Mia Lamar, Dow Jones Newswires; 212-416-3207; [email protected]

Stocks mentioned in the article : Vanda Pharmaceuticals Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
10/18 VANDA PHARMACEUTICALS INC. : Other Events (form 8-K)
10/11 VANDA PHARMACEUTICALS : Announces Participation at the Oppenheimer Specialty Pha..
10/04 VANDA PHARMACEUTICALS : to Present Tradipitant Phase II Atopic Dermatitis Data a..
10/03 VANDA PHARMACEUTICALS : to Present Scientific Posters at World Sleep 2017
10/02 VANDA PHARMACEUTICALS : to Present Tradipitant Phase II Atopic Dermatitis Data a..
09/29 VANDA PHARMACEUTICALS : to Present Scientific Posters at World Sleep 2017
09/14 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Other Events
09/14 BIOTECH MOVERS : Amicus Therapeutics, Inc. (NASDAQ:FOLD) And Vanda Pharmaceutica..
09/14 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Financial Statements and..
09/13 VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
More news
News from SeekingAlpha
10/18 Price of Vanda's Hetlioz set at ?69K in Germany
09/15 Vanda Pharmaceuticals On Improving Itch and Disease Severity in Patients with..
09/14 Vanda Pharmaceuticals (VNDA) Presents At Morgan Stanley 15th Annual Global He..
09/13 After Hours Gainers / Losers
09/13 Vanda's tradipitant shows mixed results in mid-stage dermatitis study
Financials ($)
Sales 2017 170 M
EBIT 2017 -18,4 M
Net income 2017 -14,9 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 4,21x
Capi. / Sales 2018 3,49x
Capitalization 715 M
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Technical analysis trends VANDA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 22,0 $
Spread / Average Target 38%
EPS Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS INC.0.00%715
GILEAD SCIENCES11.73%104 487
REGENERON PHARMACEUTICALS19.69%47 079
VERTEX PHARMACEUTICALS110.07%39 018
ACTELION23.81%29 869
GENMAB14.75%12 912